Cochrane · systematic review · CD013238
Anti‐epidermal growth factor receptor therapy for glioblastoma in adults
Lee, A, Arasaratnam, M, Chan, DLok Hang, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 85.7%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐EGFR therapy compared to placebo or standard of care for glioblastoma in adults
Population: glioblastoma in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ‐ first‐line studies Anti‐EGFR therapy vs placebo or standard of care | HR 0.89 [0.76, 1.04] | 3 studies · 1000 participants | Moderate Downgraded: risk of bias, indirectness |
Overall survival ‐ recurrent disease studies Anti‐EGFR therapy vs placebo or standard of care | HR 0.79 [0.51, 1.21] | 4 studies · 489 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Lymphopenia Anti‐EGFR therapy vs placebo or standard of care | OR 0.97 [0.19, 4.81] | 4 studies · 1146 participants | Low Downgraded: risk of bias, inconsistency |
Neutropenia Anti‐EGFR therapy vs placebo or standard of care | OR 1.29 [0.82, 2.03] | 4 studies · 1146 participants | Low Downgraded: risk of bias, inconsistency |
Thrombocytopenia Anti‐EGFR therapy vs placebo or standard of care | OR 3.69 [0.51, 26.51] | 4 studies · 1146 participants | Low Downgraded: risk of bias, inconsistency |
Progression‐free survival ‐ first‐line studies Anti‐EGFR therapy vs placebo or standard of care | HR 0.94 [0.81, 1.1] | 2 studies · 894 participants | Low Downgraded: risk of bias, indirectness |
Progression‐free survival ‐ recurrent disease studies Anti‐EGFR therapy vs placebo or standard of care | HR 0.75 [0.58, 0.96] | 3 studies · 275 participants | Low Downgraded: indirectness |